Science

Having long been recognised as crucial mediators of innate immunity, neutrophils provide the first line of defence against invading microorganisms and inflammatory insults, capable of mobilizing innate and adaptive responses to return to homeostasis.

At LIfT Biosciences, we are producing a unique type of innate immune cell called a Immunomodulatory Alpha Neutrophil (IMAN). IMAN's exhibit a dual mode of action that enables them to be both exceptional cytotoxic directly and immunomodulatory to recruit the rest of the immune system also to destroy solid tumours. LIfT is the only Biotech company in the world with a Neutrophil Based Cell Therapy Platform.

​

N-LIfT cells differentiate in vivo into Immunomodulatory Alpha Neutrophils (IMANs) that have the potential to overcome hurdles encountered by other cell therapies in the treatment of solid tumours. IMANs are:

• Allogeneic, straightforward to scale, cost effective and off-the-shelf 

• Innate antigen-independent mechanism-of-action

• Actively recruited into the tumour microenvironment

• Stable and capable of overcoming immunosuppressive tumour microenvironments

• Capable of orchestrating patients own anti-tumour immune responses